Table 5. Outcomes.
| Study | Follow up | THI | TRQ | THQ | TQ | TFI | Annoyance | Loudness |
|---|---|---|---|---|---|---|---|---|
| Without sound pairing | ||||||||
| Suk, 2018 | Pre-treatment | 45 (± 19) | x | x | x | x | x | x |
| Immediately after treatment | 27 (± 15) | x | x | x | x | 33.3% (n = 8) responders | 45.8% (n = 11) responders | |
| Wichova, 2018 | Pre-operative | x | x | x | x | x | x | 5.85 (± 1.5) |
| Post-operative | 41.75 (± 22.6) | x | x | x | x | x | 3.8 (± 1.4) | |
| Kreuzer, 2014 | Pre-treatment | 50.0 (± 19.4) | x | x | 48.8 (± 11.7) | 6.8 (± 2.1) | 6.8 (± 1.9) | |
| phase 1 | Immediately after treatment | 49.4 (± 21.8)* | x | x | 45.2 (±14.8)# | 7.1 (± 2.2)* | 6.9 (± 1.9)* | |
| With sound pairing | ||||||||
| Tyler, 2017 | Immediately after treatment ∞ | Intervention: -17.7 (-28 to -7.3)# | x | Intervention: -2.5 (-8.3 to -3.3) | x | Intervention: -2.03 (-7.1 to 3.1) | x | Intervention: -6.69 (-13.26 to -0.11) |
| Control: -7.3 (-27.5 to 12.7) * | Control: -7.5 (-15.8 to 0.7) | Control: -7.5 (-15.5 to 0.7) | Control: -8.5 (-22.6 to 5.5) | |||||
| End of follow-up £ | Intervention: -19.39 (-37.99, -0.79) # | x | Intervention: -11.99 (-19.72, -4.26) # | x | Intervention: -9.98 (-19.74, -0.21)# | x | Intervention: -19.41 (-34.01, -4.82) # | |
| De Ridder, 2015 | Pre-treatment | 50 | 55 | 63 | x | x | x | |
| Immediately after treatment | 26 | 17 | 40 | x | x | x | ||
| End follow-up | 21 | 40 | 45 | x | x | x | ||
| Shim, 2015 | Pre-treatment | 41.50 (± 29.64) | x | x | x | x | 6.32 (± 2.06) | |
| Immediately after treatment | 35.46 (± 23.30)* | x | x | x | x | 5.16 (± 1.52) # | ||
| Kreuzer, 2014 | Pre-treatment | 55.3 (± 21.3) | x | x | 52.6 (±14.8) | 7.0 (± 2.0) | 7.0 (± 1.6) | |
| phase 2 | Immediately after treatment | 58.0 (± 25.3) | x | x | 49.8 (± 19.0) | 7.4 (± 2.1) | 7.3 (± 2.0) | |
| End of follow-up | 57.0 (± 26.2)* | x | x | 49.8 (±19.5)* | 7.3 (± 2.2)* | 7.1 (± 2.0)* | ||
| Mei, 2014¥ | Pre-treatment | Score 0–36: VNS 13/50 | x | x | x | x | x | |
| Control 13/46 | ||||||||
| Score 38–100: VNS 37/50 | ||||||||
| Control 33/46 | ||||||||
| Immediately after treatment | Score 0–36: VNS 38/50 # | x | x | x | x | x | ||
| Control 21/46 | ||||||||
| Score 38–100: VNS 12/50# | ||||||||
| Control 25/46* | ||||||||
| De Ridder, 2014 | Pre-treatment | 69.6 | 66.6 | 72.0 | x | x | x | |
| Immediately after treatment | 61.4 | 56.0 | 67.3 | x | x | x | ||
| End follow-up | 62.0 | 56.0 | 68.5 | x | x | x | ||
| Lehtimäki, 2013 | Pre-treatment | 70 | x | x | 12† | 61 | 59 | |
| Immediately after treatment | 39 | x | x | 10† | 40 | 38 | ||
Numbers present outcome measurement with standard deviations in brackets when given.
x = not reported
* = not statistically significant
# = statistically significant
† = mini-TQ
¥ = reporting numbers of tinnitus ears per group within outcome scores of an individual test; ∞ = scores reported in change from baseline, in brackets 95% confidence intervals
£ = scores reported in change from baseline, in brackets: lower CI, upper CI, n participants.